β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis
British Journal of Clinical Pharmacology · 2025-02 · 91 (2) · 325-337
DOI: 10.1111/bcp.16361 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.12.2024. Verfasst von Lujain Ez Eddin und 5 weiteren Autor:innen. Beteiligte Einrichtung: ICES Western, London, ON, Canada. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Mental Disorders. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
This systematic review and meta‐analysis aimed to evaluate the association between β‐blocker use and neuropsychiatric adverse events, specifically focusing on short‐term outcomes.
Methods
A comprehensive literature search identified studies reporting neuropsychiatric outcomes in patients using β‐blockers, including randomized controlled trials and observational studies. Relative risks (RR) and 95% confidence intervals (CIs) were calculated for outcomes such as dizziness, insomnia, nightmares, drowsiness and delirium.
Results
Our analysis revealed that β‐blocker use was significantly associated with an increased risk of dizziness (RR 1.72, 95% CI [1.39–2.14]; I 2 = 1%, 14 studies) compared to placebo. Lipophilic β‐blockers, especially propranolol, showed an even greater risk of dizziness (RR 3.13, 95% CI [1.44–6.84]; I 2 = 0%, three studies). Propranolol was also associated with increased insomnia risk compared to placebo (RR 1.13, 95% CI [1.00–1.28]; I 2 = 0%, five studies). Our data did not show statistically significant increases in the reports of nightmares and somnolence. Other adverse effects, including drowsiness, sleep disturbances, hallucinations and delirium, were noted.
Conclusions
Our findings suggest a significant association between β‐blocker use and an increased risk of neuropsychiatric adverse events, particularly insomnia and dizziness with higher risks associated with lipophilic β‐blocker use. Given the ambiguity surrounding dizziness and its classification as a neuropsychiatric effect, our findings are exploratory, and we cannot exclude a potential cardiovascular origin for dizziness. Most studies (75%) were published before the CONSORT statement in 1996, indicating potential reporting limitations and a lack of recent research. Additionally, 60% of studies had a high risk of bias, underscoring the need for more rigorous and contemporary investigations into the neuropsychiatric implications of β‐blocker use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICES Western, London, ON, Canada.
- Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.
- Department of Epidemiology & Biostatistics, Western University, London, ON, Canada.
- Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada.
ORCID-Profile: Mohammad Ali Omrani, Flory T Muanda
Zitieren
APA
Eddin, L. E., Preyra, R., Ahmadi, F., Jafari, A., Omrani, M. A., & Muanda, F. T. (2025). β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology, 91(2), 325-337. https://doi.org/10.1111/bcp.16361
Vancouver
Eddin LE, Preyra R, Ahmadi F, Jafari A, Omrani MA, Muanda FT. β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2025;91(2):325-337. doi:10.1111/bcp.16361
BibTeX
@article{Eddin2025,
author = {Eddin, Lujain Ez and Preyra, Rebecca and Ahmadi, Fatemeh and Jafari, Atefeh and Omrani, Mohammad Ali and Muanda, Flory T},
title = {β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {2},
pages = {325--337},
doi = {10.1111/bcp.16361}
}
EUVIMED